Latest sensyne publications

UK clinical healthcare disruptor signs first major drug development deal since IPO Sensyne Health has struck a two year deal with pharmaceutical giant Bayer to develop new treatments for cardiovascular disease using Sensyne’s AI technology. The NHS Long Term Plan has identified the prevention of cardiovascular disease, which currently affects 7 million people in the… Read More